New treatment options for acute edema attacks caused by hereditary angioedema

American Journal of Health-System Pharmacy

Volumn 68, Issue 22, 2011, Pages 2129-2138

  Thomas, Michael C ^a   Shah, Samit ^a  

^a SOUTHERN UNIVERSITY   (United States)

Author keywords

Angioedema; Antiinflammatory agents; C1 esterase inhibitor; Complement inhibitors; Diagnosis; Dosage; Ecallantide; Epidemiology; Icatibant; Mechanism of action

Indexed keywords

ADRENALIN; ALBUMIN; ANABOLIC AGENT; ANTIEMETIC AGENT; ANTIFIBRINOLYTIC AGENT; ANTIHISTAMINIC AGENT; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; KALLIKREIN; NARCOTIC AGENT; PLACEBO; PREKALLIKREIN; TRANEXAMIC ACID;

ABDOMEN; ABDOMINAL DISEASE; ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; ASTHENIA; DIARRHEA; DISEASE DURATION; DIZZINESS; EDEMA; FACE; FEVER; GASTROINTESTINAL EDEMA; GENE MUTATION; HEADACHE; HUMAN; INJECTION SITE PAIN; LABORATORY TEST; LARYNX; LIVER FUNCTION; NAUSEA; NOSE CONGESTION; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RASH; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN EDEMA; SKIN SWELLING; TACHYCARDIA; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT; URTICARIA; VERTIGO; VOMITING;

EID: 81155134308     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100718     Document Type: Review

References (65)

1. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008; 359:1027-36.
2. Bernstein IL. Hereditary angioedema: a current state-of-the-art review, II: historical perspective of non-histamine-induced angioedema. Ann Allergy Asthma Immunol. 2008; 100(suppl 2):S2-6.
3. Bowen T, Cicardi M, Bork K et al. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol. 2008; 100(suppl 2):S30-40.
4. Bowen T, Cicardi M, Farkas H et al. Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol. 2004; 114:629-37. (Pubitemid 39194940)
5. Bowen T, Cicardi M, Farkas H et al. 2010 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Allergy Asthma Clin Immunol. 2010; 6:24.
6. Cinryze (C1 esterase inhibitor [human]) package insert. Exton, PA: ViroPharma Biologics Inc.; 2010 Mar.
7. Berinert (C1 esterase inhibitor [human]) package insert. Kankakee, IL: CSL Behring LLC; 2009 Oct.
8. Kalbitor (ecallantide) package insert. Cambridge, MA: Dyax Corp.; 2009 Dec.
9. Morgan BP. Hereditary angioedema - therapies old and new. N Engl J Med. 2010; 363:581-3.
10. Zuraw BL. Hereditary angioedema: a current state-of-the-art review, IV: shortand long-term treatment of hereditary angioedema: out with the old and in with the new? Ann Allergy Asthma Immunol. 2008; 100(suppl 2):S13-8.
11. Roche O, Blanch A, Caballero T et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol. 2005; 94:498-503. (Pubitemid 40547939)
12. Stray-Pedersen A, Abrahamsen TG, Froland SS. Primary immunodeficiency diseases in Norway. J Clin Immunol. 2000; 20:477-85. (Pubitemid 32099713)
13. Bork K, Meng G, Staubach P et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006; 119:267-74. (Pubitemid 43255068)
14. Cugno M, Zanichelli A, Foieni F et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 2009; 15:69-78.
15. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001; 161:2417-29. (Pubitemid 33043115)
16. Agostoni A, Aygoren-Pursun E, Binkley KE et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004; 114(suppl):S51-131.
17. Levy JH, O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs. 2006; 15:1077-90. (Pubitemid 44314659)
18. Makrides SC. Therapeutic inhibition of the complement system. Pharmacol Rev. 1998; 50:59-87. (Pubitemid 28158842)
19. Hu VW, Esser AF, Podack ER et al. The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane. J Immunol. 1981; 127:380-6. (Pubitemid 11075512)
20. Podack ER, Muller-Eberhard HJ, Horst H et al. Membrane attach complex of complement (MAC): three-dimensional analysis of MAC-phospholipid vesicle recombinants. J Immunol. 1982; 128:2353-7. (Pubitemid 12086536)
21. Davis AE 3rd. New treatments addressing the pathophysiology of hereditary angioedema. Clin Mol Allergy. 2008; 6:2.
22. Davis AE 3rd. The pathogenesis of hereditary angioedema. Transfus Apher Sci. 2003; 29:195-203.
23. Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci U S A. 2002; 99:896-900. (Pubitemid 34106607)
24. Joseph K, Tholanikunnel BG, Kaplan AP. Activation of the bradykinin-forming cascade on endothelial cells: a role for heat shock protein 90. Int Immunopharmacol. 2002; 2:1851-9. (Pubitemid 35373926)
25. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem. 2002; 277:17962-9. (Pubitemid 34967607)
26. Davis AE 3rd. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol. 2008; 100(suppl 2):S7-12.
27. Amara U, Rittirsch D, Flierl M et al. Interaction between the coagulation and complement system. Adv Exp Med Biol. 2008; 632:71-9.
28. Davis AE 3rd. The pathophysiology of hereditary angioedema. Clin Immunol. 2005; 114:3-9.
29. Strang CJ, Cholin S, Spragg J et al. Angioedema induced by a peptide derived from complement component C2. J Exp Med. 1988; 168:1685-98. (Pubitemid 19023256)
30. Shoemaker LR, Schurman SJ, Donaldson VH et al. Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability-enhancing activities. Clin Exp Immunol. 1994; 95:22-8. (Pubitemid 24207098)
31. Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous"formation of bradykinin. J Allergy Clin Immunol. 1983; 72:54-60. (Pubitemid 13069361)
32. Curd JG, Prograis LJ Jr, Cochrane CG. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J Exp Med. 1980; 152:742-7. (Pubitemid 10059504)
33. Han ED, MacFarlane RC, Mulligan AN et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002; 109:1057-63. (Pubitemid 34408580)
34. Nussberger J, Cugno M, Amstutz C et al. Plasma bradykinin in angio-oedema. Lancet. 1998; 351:1693-7. (Pubitemid 28254530)
35. Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angiooedema. Allergy. 2008; 63:751-7. (Pubitemid 351591842)
36. Bork K, Hardt J, Schicketanz KH et al. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003; 163:1229-35. (Pubitemid 36613077)
37. Zuraw BL. Diagnosis and management of hereditary angioedema: an American approach. Transfus Apher Sci. 2003; 29:239-45. (Pubitemid 37321354)
38. Gompels MM, Lock RJ, Abinun M et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005; 139:379-94. (Pubitemid 40333248)
39. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001; 161:714-8. (Pubitemid 32200225)
40. Bork K, Staubach P, Eckardt AJ et al. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006; 101:619-27. (Pubitemid 43340941)
41. Prematta M, Gibbs JG, Pratt EL et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2007; 98:383-8. (Pubitemid 46582131)
42. Cicardi M, Zingale L. How do we treat patients with hereditary angioedema? Transfus Apher Sci. 2003; 29:221-7. (Pubitemid 37315586)
43. Frank MM. Hereditary angioedema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema. Ann Allergy Asthma Immunol. 2008; 100(suppl 2):S23-9.
44. Caliezi C, Wuillemin WA, Zeerleder S et al. C1-esterase inhibitor: an antiinflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev. 2000; 52:91-112. (Pubitemid 30127596)
45. Krassilnikova SI, Nikiforov YS, Craig TJ. Treatment of hereditary angioedema: current perspectives. Recent Pat Inflamm Allergy Drug Discov. 2008; 2:166-74.
46. Frank MM, Jiang H. New therapies for hereditary angioedema: disease outlook changes dramatically. J Allergy Clin Immunol. 2008; 121:272-80.
47. Epstein TG, Bernstein JA. Current and emerging management options for hereditary angioedema in the US. Drugs. 2008; 68:2561-73.
48. Craig TJ, Levy RJ, Wasserman RL et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009; 124:801-8.
49. Kunschak M, Engl W, Maritsch F et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion. 1998; 38:540-9. (Pubitemid 28317229)
50. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996; 334:1630-4. (Pubitemid 26192522)
51. Zuraw B, Busse P, White M et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010; 363:513-22.
52. Bork K, Meng G, Staubach P et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion. 2005; 45:1774-84. (Pubitemid 43923905)
53. Farkas H, Jakab L, Temesszentandrasi G et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol. 2007; 120:941-7. (Pubitemid 47531846)
54. Markland W, Ley AC, Ladner RC. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry. 1996; 35:8058-67. (Pubitemid 26202548)
55. Markland W, Ley AC, Lee SW et al. Iterative optimization of high-affinity protease inhibitors using phage display. 1. Plasmin. Biochemistry. 1996; 35:8045-57. (Pubitemid 26202547)
56. Bernstein JA, Qazi M. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol. 2010; 6:29-39.
57. Zuraw B, Yasothan U, Kirkpatrick P. Ecallantide. Nat Rev Drug Discov. 2010; 9:189-90. News.
58. Cicardi M, Levy RJ, McNeil DL et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010; 363:523-31.
59. Bork K, Yasothan U, Kirkpatrick P. Icatibant. Nat Rev Drug Discov. 2008; 7:801-2.
60. Hock FJ, Wirth K, Albus U et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991; 102:769-73.
61. Wirth K, Hock FJ, Albus U et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991; 102:774-7.
62. Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010; 363:532-41.
63. Longhurst HJ, Farkas H, Craig T et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010; 6:22.
64. Dagen C, Craig TJ. Treatment of hereditary angioedema: items that need to be addressed in practice parameter. Allergy Asthma Clin Immunol. 2010; 6:11.
65. Wuillemin WA. Therapeutic agents for hereditary angioedema. N Engl J Med. 2011; 364:84-5. Letter.